BioSpace News Archive

Active Biotech announced that its board of directors has approved the company’s new direction. The focus is on the company’s wholly-owned lead assets, laquinimod and tasquinimod.

One entity will focus on pharmaceuticals and drug development, while the other will be aimed at consumer healthcare.

Aimmune announced a licensing deal with Xencor for the investigational humanized monoclonal antibody XmAb7195, which has been redubbed AIMab7195.

Martin Tolar, chief executive officer of Alzheon, told BioSpace that his company’s drug was designed to inhibit the formation of toxic soluble amyloid oligomers.

The first few minutes of your job interview are critical, as studies show hiring managers form strong impressions to make their hiring decisions based on these early minutes of the interview.

Pharma and life science companies from across the globe provide updates on their pipelines and businesses.

Findacure co-founder will apply extensive drug repurposing and rare disease expertise to progress Healx’s drug candidates into the clinic.

In response to the global health emergency caused by the recent outbreak of coronavirus strain 2019-nCoV, LGC’s SeraCare Life Sciences, a manufacturer and leading partner to global in vitro diagnostic manufacturers and clinical laboratories, is announcing the development of molecular reference materials for coronavirus utilizing their proprietary AccuPlex™ recombinant technology.

Collaborative Project with The Myositis Association To Be Featured at Summit

Recipharm announced on 4 February 2020 that the offer to acquire Consort Medical plc had become unconditional in all respects and will remain open for acceptances for a further 14 days, until 18 February 2020.